Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group. Burnett AK, et al. Among authors: milligan d. Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1. Blood. 2015. PMID: 25833957 Free PMC article. Clinical Trial.
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. Burnett AK, et al. Among authors: milligan d. Cancer. 2007 Mar 15;109(6):1114-24. doi: 10.1002/cncr.22496. Cancer. 2007. PMID: 17315155 Free article. Clinical Trial.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Among authors: milligan d. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. Burnett AK, et al. Among authors: milligan d. J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385984 Clinical Trial.
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, Milligan D; AML Working Group of the UK National Cancer Research Institute. Burnett AK, et al. Among authors: milligan d. Br J Haematol. 2012 Aug;158(4):519-22. doi: 10.1111/j.1365-2141.2012.09165.x. Epub 2012 May 29. Br J Haematol. 2012. PMID: 22639959 Free article. Clinical Trial.
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK; UK National Cancer Research Institute AML Working Group. Burnett AK, et al. Among authors: milligan d. Blood. 2013 Aug 22;122(8):1384-94. doi: 10.1182/blood-2013-04-496596. Epub 2013 Jul 9. Blood. 2013. PMID: 23838349 Free article. Clinical Trial.
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH; UK National Cancer Research Institute AML Working Group. Burnett AK, et al. Among authors: milligan d. Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14. Leukemia. 2013. PMID: 22964882 Clinical Trial.
385 results